# DEVELOPMENT OF A BROAD-SPECTRUM THERAPEUTIC

> **NIH NIH N01** · ABVIRO, LLC · 2022 · $2,600,780

## Abstract

To support the development of therapeutic products for use in post-event settings following the intentional release of a NIAID Category A, B, or C Priority Pathogen or in response to naturally occurring outbreaks of infectious diseases caused by these pathogens; includes the conduct of a Phase I clinical trial.

## Key facts

- **NIH application ID:** 10551007
- **Project number:** 272201600028C-P00015-9999-1
- **Recipient organization:** ABVIRO, LLC
- **Principal Investigator:** URBAN RAMSTEDT
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $2,600,780
- **Award type:** —
- **Project period:** 2016-09-23 → 2022-06-25

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10551007

## Citation

> US National Institutes of Health, RePORTER application 10551007, DEVELOPMENT OF A BROAD-SPECTRUM THERAPEUTIC (272201600028C-P00015-9999-1). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/10551007. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*